Key facts
- ChuanXin Biomedicine’s last known valuation is $174.3M (Jan 2025).
- It has raised $63.9M; the latest was Secondary Transaction - Private in Aug 2025.
- Notable investors include YuanBio Venture Capital, Hongtai Capital Holdings, CCB International, BCHT, Herui Venture Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ChuanXin Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for ChuanXin Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ChuanXin Biomedicine
Developer of RNA-based drugs, designed to address infectious diseases and cancer treatments. The company develops new generations of mRNA vaccines to more efficiently prevent COVID-19, providing patients revolutionary medical products to better improve the healthcare.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- themediumtx.com/
- Ownership
- Privately Held (backing)
ChuanXin Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChuanXin Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChuanXin Biomedicine in its N-PORT filings yet. We sweep new filings monthly.